Showing 81-100 of 642 for: Cochrane Systematic Reviews > Cardiovascular 
- Beta-blocker therapy for tremor in Parkinson's disease
Cochrane Systematic Reviews, 11-Nov-2008
The tremor of Parkinson's disease can cause considerable disability for the individual concerned. Traditional antiparkinsonian therapies such as levodopa have only a minor effect on tremor. Beta-blockers are used to attenuate other forms of tremor such as
- Beta-blockers for hypertension
Cochrane Systematic Reviews, 27-Aug-2012
This review is an update of the Cochrane Review published in 2007, which assessed the role of beta-blockade as first-line therapy for hypertension.
- Bispectral index for improving anaesthetic delivery and postoperative recovery
Cochrane Systematic Reviews, 10-Jun-2014
The use of clinical signs may not be reliable in measuring the hypnotic component of anaesthesia. The use of bispectral index (BIS) to guide the dose of anaesthetic may have certain advantages over clinical signs. This is the second update of a review ori
- Blood pressure lowering efficacy of alpha blockers for primary hypertension
Cochrane Systematic Reviews, 10-Jul-2012
Alpha blockers are occasionally prescribed for hypertension so it is important to determine and compare their effects on blood pressure (BP), heart rate and withdrawals due to adverse effects (WDAE).
- Blood pressure lowering efficacy of beta-blockers as second-line therapy for primary hypertension
Cochrane Systematic Reviews, 11-Nov-2009
Beta-blockers are one of the more commonly prescribed classes of anti-hypertensive drugs, both as first-line and second-line.
- Blood pressure lowering efficacy of coenzyme Q10 for primary hypertension
Cochrane Systematic Reviews, 3-Mar-2016
Blood pressure is a commonly measured risk factor for non-fatal and fatal cardiovascular adverse events such as heart attacks and strokes. Clinical trials have suggested that coenzyme Q10, a non-prescription nutritional supplement, can effectively lower b
- Blood pressure lowering efficacy of diuretics as second-line therapy for primary hypertension
Cochrane Systematic Reviews, 12-Aug-2009
Diuretics are widely prescribed for hypertension not only as a first-line drug but also as a second-line drug. Therefore, it is essential to determine the effects of diuretics on blood pressure (BP), heart rate and withdrawals due to adverse effects (WDAE
- Blood pressure lowering efficacy of potassium-sparing diuretics (that block the epithelial sodium channel) for primary hypertension
Cochrane Systematic Reviews, 18-Oct-2012
Potassium-sparing diuretics, which block the epithelial sodium channel (ENaC), are widely prescribed for hypertension as a second-line drug in patients taking other diuretics (e.g. thiazide diuretics) and much less commonly prescribed as monotherapy. Ther
- Blood pressure lowering efficacy of reserpine for primary hypertension
Cochrane Systematic Reviews, 12-Aug-2009
Many antihypertensive agents exist today for the treatment of primary hypertension (systolic blood pressure =140 mmHg and/or diastolic blood pressure =90 mmHg). Randomised controlled trials have been carried out to investigate the evidence for these agent
- Blood pressure lowering in patients without prior cerebrovascular disease for prevention of cognitive impairment and dementia
Cochrane Systematic Reviews, 9-Aug-2009
This is an update of a previous review (McGuinness 2006).
- Blood pressure-lowering efficacy of loop diuretics for primary hypertension
Cochrane Systematic Reviews, 14-May-2015
Antihypertensive drugs from the thiazide diuretic drug class have been shown to reduce mortality and cardiovascular morbidity. Loop diuretics are indicated and used to treat hypertension, but a systematic review of their blood pressure-lowering efficacy o
- Bradykinin beta-2 receptor antagonists for acute traumatic brain injury
Cochrane Systematic Reviews, 20-May-2010
Traumatic brain injury (TBI) is a leading cause of death and disability worldwide. Cerebral oedema, the accumulation of fluid within the brain, is believed to be an important contributor to the secondary brain damage that occurs following injury. The rele
- Buflomedil for intermittent claudication
Cochrane Systematic Reviews, 19-Feb-2013
Intermittent claudication (IC) is pain caused by chronic occlusive arterial disease, that develops in a limb during exercise and is relieved with rest. Buflomedil is a vasoactive agent used to treat peripheral vascular disease. However, its clinical effic
- Bypass surgery for chronic lower limb ischaemia
Cochrane Systematic Reviews, 8-May-2008
Surgical bypass of an occluded arterial segment is one of the mainstay treatments for patients with critical limb ischaemia (CLI). However, it was introduced without formal evaluation.
- Calcium antagonists for acute ischemic stroke
Cochrane Systematic Reviews, 13-Feb-2019
The sudden loss of blood supply in ischemic stroke is associated with an increase of calcium ions within neurons. Inhibiting this increase could protect neurons and might reduce neurological impairment, disability, and handicap after stroke.
- Calcium antagonists for aneurysmal subarachnoid haemorrhage
Cochrane Systematic Reviews, 22-Jul-2008
Secondary ischaemia is a frequent cause of poor outcome in patients with subarachnoid haemorrhage (SAH). Its pathogenesis has been incompletely elucidated, but vasospasm probably is a contributing factor. Experimental studies have suggested that calcium a
- Calcium channel blockers for acute traumatic brain injury
Cochrane Systematic Reviews, 12-Aug-2008
Acute traumatic brain injury is a major cause of death and disability. Calcium channel blockers (calcium antagonists) have been used in an attempt to prevent cerebral vasospasm after injury, maintain blood flow to the brain, and so prevent further damage.
- Calcium channel blockers for inhibiting preterm labour and birth
Cochrane Systematic Reviews, 2-Jul-2014
Preterm birth is a major contributor to perinatal mortality and morbidity, affecting around 9% of births in high-income countries and an estimated 13% of births in low- and middle-income countries. Tocolytics are drugs used to suppress uterine contraction
- Calcium channel blockers for neuroleptic-induced tardive dyskinesia
Cochrane Systematic Reviews, 1-May-2013
Schizophrenia and related disorders affect a sizable proportion of any population. Neuroleptic (antipsychotic) medications are the primary treatment for these disorders. Neuroleptic medications are associated with a variety of side effects including tardi
- Calcium channel blockers for potential impaired fetal growth
Cochrane Systematic Reviews, 2-Aug-2009
Calcium channel blockers may increase the blood flow to the fetus or may improve fetal-placental cellular energy generation. This could enhance fetal growth.
